1.8107.74% ( +0.130 )
Closed: Nov 20, 16:00:00 (EDT)Valuation
Current ValuationThe current P/E ratio is -2.32, within the reasonable range, cheaper than 61.73% of the time in the past 3 years, and the industry ranks 317/607, the industry Median -1.63.
-2.32xP/E
$1.68Stock price
$-0.72Earnings per share
-2.32xP/E
Stock price$1.68Earnings per share$-0.72
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -1.75x
- Typical range
- -3.31x–-0.88x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
013263952
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
GILDUSGilead Sciences | -53.48x | 162.72% | $206.55B |
MRNAUSModerna | -28.53x | 0.44% | $79.58B |
CSLLYUSCSL Limited | -24.52x | -- | $63.24B |
NTRAUSNatera | -255.23x | 4.11% | $42.04B |
RVMDUSRevolution Medicines | -18.27x | 40.11% | $34.17B |
INSMUSInsmed | -52.33x | 74.85% | $31.69B |
ROIVUSRoivant Sciences | -81.98x | 102.68% | $28.23B |
BNTXUSBioNTech SE | -11.92x | 26.17% | $20.18B |
BBIOUSBridgebio Pharma | -25.72x | 31.00% | $15.23B |
BMRNUSBioMarin Pharma | -622.38x | 55.46% | $11.90B |
KYMRUSKymera Therapeutics | -28.41x | 8.74% | $9.93B |
SYREUSSpyre Therapeutics | -41.39x | 59.92% | $9.27B |
PCVXUSVaxcyte | -8.04x | 42.32% | $9.24B |
MDGLUSMadrigal Pharma | -59.28x | 86.62% | $9.22B |
PRAXUSPraxis Precision Medicines | -24.18x | 0.35% | $8.69B |
SMMTUSSummit Therapeutics | -10.13x | 24.19% | $8.43B |
RYTMUSRhythm Pharma | -40.84x | 51.65% | $8.10B |
ALKSUSAlkermes | -22,108.98x | 133.70% | $7.76B |
TWSTUSTwist Bioscience | -56.44x | 34.79% | $7.35B |
CGONUSCG oncology | -30.81x | 41.23% | $7.32B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
